Evidence map›Paper›PMID 30315273›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients.

Ana M Bolivar, Rajyalakshmi Luthra, Meenakshi Mehrotra, Wei Chen, Bedia A Barkoh, Peter Hu, Wei Zhang, Russell R Broaddus

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05955079 unknown statusnot on this mapstarted 2021, after this paper: background citation

Prospective Validation of the Association Between Circulating Tumor DNA Detection and Risk of Metastatic Relapse in Patients With Localized Endometrial Cancer

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2021 to 2026Enrolled130ConditionsEndometrial CancerArmsWhole blood
NCT06680791 recruitingnot on this mapstarted 2024, after this paper: background citation

Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors

TypeobservationalSponsorLukas VanekRan2024 to 2028Enrolled280ConditionsEndometrial Cancer, Genetic Predisposition, Risk Behavior
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ana M BolivarSchool of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meenakshi MehrotraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei ChenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bedia A BarkohDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter HuSchool of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei ZhangDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Russell R BroaddusDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rbroaddus@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USWake Forest University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50 CA09825
6 · The paper itself

Abstract

There is currently no blood-based marker in routine use for endometrial cancer patients. Such a marker could potentially be used for early detection, but it could also help to track tumor recurrence following hysterectomy. This is important, as extra-vaginal recurrence of endometrial endometrioid adenocarcinoma is usually incurable. This proof-of-principle study was designed to determine if tumor-associated mutations could be detected in cell-free DNA from the peripheral blood of early and late stage endometrial endometrioid carcinoma patients. Approximately 90% of endometrioid carcinomas have at least one mutation in the genes CTNNB1, KRAS, PTEN, or PIK3CA. Using a custom panel targeting 30 hotspot amplicons in these four genes, next-generation sequencing was performed on cell-free DNA extracted from plasma obtained from a peripheral blood draw at the time of hysterectomy and the matching tumor DNA from 48 patients with endometrioid endometrial carcinomas. At least one mutation in the tumor was detected in 45/48 (94%) of patients. Fifteen of 45 patients (33%) had a mutation in the plasma that matched a mutation in the tumor. These same mutations were not detected in the matched negative control buffy coat. Presence of a plasma mutation was significantly associated with advanced stage at hysterectomy, deep myometrial invasion, lymphatic/vascular invasion, and primary tumor size. Detecting a plasma-based mutation was independent of the amount of cell-free DNA isolated from the plasma. Overall, 18% of early stage patients had a mutation detected in the plasma. These results demonstrate that mutations in genes relevant to endometrial cancer can be identified in the peripheral blood of patients at the time of surgery. Future studies can help to determine the post-operative time course of mutation clearance from the peripheral blood and if mutation re-emergence is predictive of recurrence.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, EndometrioidCirculating Tumor DNAEndometrial NeoplasmsFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedMutationNeoplasm Recurrence, LocalBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID30315273
PMCPMC6395490
OpenAlexW2896196924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.